The estimated Net Worth of Bryan M. Reasons is at least $3.3 million dollars as of 1 June 2024. Mr. Reasons owns over 4,660 units of Mallinckrodt Plc stock worth over $9,769 and over the last 9 years he sold MNK stock worth over $276,658. In addition, he makes $3,016,120 as Chief Financial Officer et Executive Vice President at Mallinckrodt Plc.
Sign up
Mr. Reasons MNK stock SEC Form 4 insiders trading
Bryan has made over 7 trades of the Mallinckrodt Plc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 4,660 units of MNK stock worth $1,584 on 1 June 2024.
The largest trade he's ever made was selling 11,698 units of Mallinckrodt Plc stock on 21 August 2018 worth over $276,658. On average, Bryan trades about 1,273 units every 59 days since 2016. As of 1 June 2024 he still owns at least 28,732 units of Mallinckrodt Plc stock.
You can see the complete history of Mr. Reasons stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Bryan Reasons biography
Bryan M. Reasons CPA serves as Chief Financial Officer, Executive Vice President of the Company. Mr. Reasons brings broad financial leadership experience toMallinckrodt, which he gained in publicly traded pharmaceutical companies known for their success in research, development and commercialization of branded drugs. Serving as Senior Vice President and Chief Financial Officer for six years at Impax Laboratories, Mr. Reasons was instrumental in the company's 2018 combination with Amneal Pharmaceuticals, Inc. He began his 25-year finance career in auditing with PricewaterhouseCoopers, and then progressed through roles of increasing finance responsibility at E. I. Du Pont De Nemours and Company, and Cephalon, Inc. Mr. Reasons also serves as an independent board director and audit committee chair for both Aclaris Therapeutics, Inc. and Recro Pharma, Inc.
What is the salary of Bryan Reasons?
As the Chief Financial Officer et Executive Vice President of Mallinckrodt Plc, the total compensation of Bryan Reasons at Mallinckrodt Plc is $3,016,120. There are 4 executives at Mallinckrodt Plc getting paid more, with Mark Trudeau having the highest compensation of $14,610,800.
How old is Bryan Reasons?
Bryan Reasons is 51, he's been the Chief Financial Officer et Executive Vice President of Mallinckrodt Plc since 2019. There are 13 older and no younger executives at Mallinckrodt Plc. The oldest executive at Mallinckrodt Plc is J. Martin Carroll, 70, who is the Independent Director.
What's Bryan Reasons's mailing address?
Bryan's mailing address filed with the SEC is McDonnell Boulevard, Hazelwood, Saint Louis County, Missouri, 63042, United States.
Insiders trading at Mallinckrodt Plc
Over the last 11 years, insiders at Mallinckrodt Plc have traded over $29,853,069 worth of Mallinckrodt Plc stock and bought 2,559,592 units worth $174,429,961 . The most active insiders traders include & Co. Inc. Paulson, James E Deerfield Mgmt L.P.... et Nancy Lurker. On average, Mallinckrodt Plc executives and independent directors trade stock every 29 days with the average trade being worth of $10,061. The most recent stock trade was executed by Jason Daniel Goodson on 16 March 2023, trading 1,133 units of MNK stock currently worth $9,495.
What does Mallinckrodt Plc do?
mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty brands segment includes branded medicines; its specialty generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the global medical imaging segment includes contrast media and nuclear imaging agents. to learn more about mallinckrodt, visit
What does Mallinckrodt Plc's logo look like?
Complete history of Mr. Reasons stock trades at Aclaris Therapeutics Inc, Recro Pharma Inc, Mallinckrodt Plc et Amneal Pharmaceuticals Inc
Mallinckrodt Plc executives and stock owners
Mallinckrodt Plc executives and other stock owners filed with the SEC include:
-
Mark Trudeau,
President, Chief Executive Officer, Director -
Steven Romano,
Executive Vice President, Chief Scientific Officer -
Hugh O'Neill,
Executive Vice President, Chief Commercial Officer -
Mark Casey,
Executive Vice President and Chief Legal Officer -
Bryan Reasons,
Chief Financial Officer, Executive Vice President -
Ian Watkins,
Chief Human Resource Officer, Executive Vice President -
Angus Russell,
Independent Non-Executive Chairman of the Board -
JoAnn Reed,
Independent Director -
J. Martin Carroll,
Independent Director -
David Norton,
Independent Director -
Kneeland Youngblood,
Independent Director -
Anne Whitaker,
Independent Director -
Paul Carter,
Independent Director -
Carlos Paya,
Independent Director -
Daniel Speciale,
Vice President - Investor Relations and IRO -
David R Carlucci,
Director -
Virgil D Thompson,
Director -
Diane H. Gulyas,
Director -
Matthew K Harbaugh,
SVP&Chief Financial Officer -
Michael Bryant Hicks,
Sr. VP & General Counsel -
Ronald K. Lloyd,
Sr. VP & Pres, Hospital -
Raymond J. Furey,
SVP & Chief Compliance Officer -
Gary M. Phillips,
Sr. VP & Chief Strategy Ofcr. -
Meredith B Fischer,
SVP, Communic. & Public Affair -
Melvin D Booth,
Director -
Joseph A Zaccagnino,
Director -
Coleman N Iii Lannum,
VP, Investor Relations -
Dagmar Rosa Bjorkeson,
Chief Strat & Corp Dev Officer -
Sigurdur O Olafsson,
President and CEO -
Kassie Harrold,
Chief Compliance Officer -
Jason Daniel Goodson,
EVP & Head of Corp Development -
Henriette Nielsen,
EVP & Chief Transformation OFC -
Lisa French,
EVP & Chief Commercial Officer -
Mark Anthony Tyndall,
EVP & Chief Legal Offi & Secre -
Stephen Andrew Welch,
EVP & Head of Spec Generics -
Frank Scholz,
SVP, Global Operations -
George A. Kegler,
EVP & CFO, Interim -
Karen Patruno Sheehy,
Sr. VP & Chief Compliance Off. -
James E Deerfield Mgmt L.P....,
-
Don M Bailey,
Director -
Sandra L Hatten,
Sr. Vice President Quality -
Terrance L Carlson,
Interim General Counsel -
& Co. Inc. Paulson,
10% owner -
Holding Ltd Enceladus,
-
Thomas E Berry,
See Remarks -
Peter G Edwards,
See Remarks -
Stefano R Carchedi,
See Remarks -
Stephen Merrick,
See Remarks -
Nancy Lurker,
Director -
Mario D. Saltarelli,
Sr. VP & Chief Science Ofcr. -
Kathy A Schaefer,
Sr. VP Fin & Corp. Controller -
Peter C Richardson,
EVP & Chief Scientific Officer -
Daniel Arthur Celentano,
Director -
Woodrow A Jr Myers,
Director -
Paul Bisaro,
Director -
James R Sulat,
Director -
Susan Michele Silbermann,
Director -
Karen Ling,
Director -
Neal P Goldman,
Director -
Riad Hussein El Dada,
Director